Retraction to: Common polymorphism in the MMP-13 gene may contribute to the risk of human cancers: a meta-analysis (Tumor Biol., (2014), 35, (10137-10148), DOI 10.1007/s13277-014-2309-y);Common polymorphism in the MMP-13 gene may contribute to the risk of human cancers: A meta-analysis

Tumor Biology

Volumn 35, Issue 10, 2014, Pages 10137-10148

  Gao, Ping ^a   Yang, Jun Lan ^a   Zhao, Hong ^a   You, Jun Hao ^a   Hu, Yi ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Cancer; Genetic polymorphism; Meta analysis; MMP 13

Indexed keywords

COLLAGENASE 3; MMP13 PROTEIN, HUMAN;

ARTICLE; ASIAN; CANCER RISK; CANCER SUSCEPTIBILITY; CAUCASIAN; CINAHL; CNKI DATABASE; COCHRANE LIBRARY; EMBASE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; MEDLINE; META ANALYSIS; PRIORITY JOURNAL; SYSTEMATIC REVIEW; WEB OF SCIENCE; ENZYMOLOGY; GENETIC PREDISPOSITION; GENETICS; NEOPLASM; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

GENETIC PREDISPOSITION TO DISEASE; HUMANS; MATRIX METALLOPROTEINASE 13; NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS;

EID: 84921502822     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-3785-4     Document Type: Erratum

References (42)

1. Izzo G, Forlenza OV, Santos B, Bertolucci PH, Ojopi EB, GattazWF, et al. Single-nucleotide polymorphisms of gsk3b, gab2 and sorl1 in late-onset alzheimer's disease: interactions with the apoe genotype. Clin (Sao Paulo). 2013; 68(2): 277-80.
2. Kwok JB, Loy CT, Hamilton G, Lau E, HalluppM, Williams J, et al. Glycogen synthase kinase-3beta and tau genes interact in alzheimer's disease. Ann Neurol. 2008; 64(4): 446-54.
3. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014; 64(1): 9-29.
4. Mehnert A, de Boer A, Feuerstein M. Employment challenges for cancer survivors. Cancer. 2013; 119 Suppl 11: 2151-9.
5. Jemal A, Bray F, Forman D, O'Brien M, Ferlay J, Center M, et al. Cancer burden in africa and opportunities for prevention. Cancer. 2012; 118(18): 4372-84.
6. Prendergast GC, Metz R, Muller AJ. Towards a genetic definition of cancer-associated inflammation: role of the ido pathway. Am J Pathol. 2010; 176(5): 2082-7.
7. Elena JW, Travis LB, Simonds NI, Ambrosone CB, Ballard-Barbash R, Bhatia S, et al. Leveraging epidemiology and clinical studies of cancer outcomes: recommendations and opportunities for translational research. J Natl Cancer Inst. 2013; 105(2): 85-94.
8. Meads C, Moore D. Breast cancer in lesbians and bisexual women: systematic review of incidence, prevalence and risk studies. BMC Public Health. 2013; 13: 1127.
9. Ye X, Fu J, Yang Y, Gao Y, Liu L, Chen S. Frequency-risk and duration-risk relationships between aspirin use and gastric cancer: a systematic review and meta-analysis. PLoS One. 2013; 8(7): e71522.
10. Woo HD, Kim J. Dietary flavonoid intake and risk of stomach and colorectal cancer. World J Gastroenterol. 2013; 19(7): 1011-9.
11. Hudson TJ. Genome variation and personalized cancer medicine. J Intern Med. 2013; 274(5): 440-50.
12. Vairaktaris E, Yapijakis C, Nkenke E, Serefoglou ZC, Chatzitheofylaktou A, Vassiliou S, et al. A metalloproteinase-13 polymorphism affecting its gene expression is associated with advanced stages of oral cancer. Anticancer Res. 2007; 27(6B): 4027-30.
13. Sanli M, Akar E, Pehlivan S, Bakir K, Tuncozgur B, Isik AF, et al. The relationship of metalloproteinase gene polymorphisms and lung cancer. J Surg Res. 2013; 183(2): 517-23.
14. Vann S, Skarstedt M, Lofgren S, Zar N, Andersson RE, Lindh M, et al. Gene polymorphism of matrix metalloproteinase-12 and-13 and association with colorectal cancer in swedish patients. Anticancer Res. 2013; 33(8): 3247-50.
15. Hadler-Olsen E, Fadnes B, Sylte I, Uhlin-Hansen L, Winberg JO. Regulation of matrix metalloproteinase activity in health and disease. FEBS J. 2011; 278(1): 28-45.
16. Radisky ES, Radisky DC. Matrix metalloproteinase-induced epithelial-mesenchymal transition in breast cancer. J Mammary Gland Biol Neoplasia. 2010; 15(2): 201-12.
17. Hwang BM, Chae HS, Jeong YJ, Lee YR, Noh EM, Youn HZ, et al. Protein tyrosine phosphatase controls breast cancer invasion through the expression of matrix metalloproteinase-9. BMB Rep. 2013; 46(11): 533-8.
18. Balbin M, Pendas AM, Uria JA, Jimenez MG, Freije JP, Lopez-Otin C. Expression and regulation of collagenase-3 (mmp-13) in human malignant tumors. APMIS. 1999; 107(1): 45-53.
19. Gonzalez-Arriaga P, Lopez-Cima MF, Fernandez-Somoano A, Pascual T, Marron MG, Puente XS, et al. Polymorphism +17 c/g in matrix metalloprotease mmp8 decreases lung cancer risk. BMC Cancer. 2008; 8: 378.
20. YamagataK, LiX, Ikegaki S, Oneyama C, Okada M, NishitaM, et al. Dissection of wnt5a-ror2 signaling leading to matrix metalloproteinase (mmp-13) expression. J Biol Chem. 2012; 287(2): 1588-99.
21. Oskarsson T. Extracellular matrix components in breast cancer progression and metastasis. Breast. 2013; 22 Suppl 2: S66-72.
22. LiY, Jia JH, Kang S, ZhangXJ, Zhao J, Wang N, et al. The functional polymorphisms on promoter region of matrix metalloproteinase-12,-13 genesmay alter the risk of epithelial ovarian carcinoma in chinese. Int J Gynecol Cancer. 2009; 19(1): 129-33.
23. Tannure PN, Kuchler EC, Falagan-Lotsch P, Amorim LM, Raggio Luiz R, Costa MC, et al. Mmp13 polymorphism decreases risk for dental caries. Caries Res. 2012; 46(4): 401-7.
24. Li Y, Sun DL, Duan YN, Zhang XJ, Wang N, Zhou RM, et al. Association of functional polymorphisms inmmps genes with gastric cardia adenocarcinoma and esophageal squamous cell carcinoma in high incidence region of north china. Mol Biol Rep. 2010; 37(1): 197-205.
25. Zhong HM, Ding QH, Chen WP, Luo RB. Vorinostat, a hdac inhibitor, showed anti-osteoarthritic activities through inhibition of inos and mmp expression, p38 and erk phosphorylation and blocking nfkappab nuclear translocation. Int Immunopharmacol. 2013; 17(2): 329-35.
26. Nannuru KC, Futakuchi M, Varney ML, Vincent TM, Marcusson EG, Singh RK. Matrix metalloproteinase (mmp)-13 regulates mammary tumor-induced osteolysis by activatingmmp9 and transforming growth factor-beta signaling at the tumor-bone interface. Cancer Res. 2010; 70(9): 3494-504.
27. Moreno-Ortiz JM, Gutierrez-Angulo M, Partida-Perez M, Peregrina-Sandoval J, Ramirez-Ramirez R, Muniz-Mendoza R, et al. Association of mmp7-181a/g and mmp13-77a/g polymorphisms with colorectal cancer in a mexican population. Genet Mol Res. 2014; 13(2): 3537-44. AOP.
28. Wang W, Wang ZC, Liu XY, Wang B, Zeng H, Mi LL, et al. Assosiation between matrix metalloproteinase 13 gene polymorphism and susceptibility to non-samall cell lung cancer. China J Mod Med. 2013; 23(1): 35-9.
29. da Costa BR, Cevallos M, Altman DG, Rutjes AW, Egger M. Uses and misuses of the strobe statement: bibliographic study. BMJ Open. 2011; 1(1): e000048.
30. Jackson D, White IR, Riley RD. Quantifying the impact of betweenstudy heterogeneity in multivariate meta-analyses. Stat Med. 2012; 31(29): 3805-20.
31. Zhang ML, Wang J, Liu C, Wang Y, Liu Y, Wang BB, et al. The functional polymorphisms on promoter region of matrix metalloproteinase-12,-13 genes with genetic susceptibility to endometriosis. Acta Univ Medicinalis Anhui. 2012; 47(3): 314-6.
32. Ioannidis JP, Patsopoulos NA, Rothstein HR. Reasons or excuses for avoiding meta-analysis in forest plots. BMJ. 2008; 336(7658): 1413-5.
33. Krane SM, Byrne MH, Lemaitre V, Henriet P, Jeffrey JJ, Witter JP, et al. Different collagenase gene products have different roles in degradation of type i collagen. J Biol Chem. 1996; 271(45): 28509-15.
34. Jia JH, Kang S, Zhao J, Zhang XJ, Wang N, Zhou RM, et al. Association of functional polymorphisms on mmp-12 and mmp-13 gene promoter region with epithelial ovarian carcinoma. Chin J Med Genet. 2010; 27(2): 209-13.
35. Zhang XJ, Guo W, Wang N, Zhou RM, Dong XJ, Li Y. The association of mmp-13 polymorphism with susceptibility to esophageal squamous cell carcinoma and gastric cardiac adenocarcinoma. Hereditas. 2006; 28(12): 1500-4.
36. Zhai Y, Qiu W, Dong XJ, Zhang XM, Xie WM, Zhang HX, et al. Functional polymorphisms in the promoters of mmp-1, mmp-2, mmp-3, mmp-9, mmp-12 and mmp-13 are not associated with hepatocellular carcinoma risk. Gut. 2007; 56(3): 445-7.
37. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002; 2(3): 161-74.
38. Tardif G, Reboul P, Pelletier JP, Martel-Pelletier J. Ten years in the life of an enzyme: the story of the human mmp-13 (collagenase-3). Mod Rheumatol. 2004; 14(3): 197-204.
39. Culhaci N, Metin K, Copcu E, Dikicioglu E. Elevated expression of mmp-13 and timp-1 in head and neck squamous cell carcinomas may reflect increased tumor invasiveness. BMC Cancer. 2004; 4: 42.
40. del Casar Lizcano JM, Vizoso Pineiro F, Gonzalez Sanchez LO, Martin Suarez A, Gava R, Cuesta Fernandez E, et al. Expression and clinical significance of collagenase-3 (mmp-13) in gastric cancer. Gastroenterol Hepatol. 2003; 26(1): 1-7.
41. Roeb E, ArndtM, Jansen B, Schumpelick V, Matern S. Simultaneous determination ofmatrixmetalloproteinase (mmp)-7, mmp-1,-3, and-13 gene expression by multiplex pcr in colorectal carcinomas. Int J Color Dis. 2004; 19(6): 518-24.
42. Yoon S, Kuivaniemi H, Gatalica Z, Olson JM, Buttice G, Ye S, et al. Mmp13 promoter polymorphismis associated with atherosclerosis in the abdominal aorta of young black males. Matrix Biol. 2002; 21(6): 487-98.